Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
10Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Oruka Therapeutics, Inc. (ORKA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
21Total relationships
3Distinct source URLs
8High confidence
0.754Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Oruka Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CMOS
CMOS
92%
we currently rely on CMOs to manufacture our product candidates
PARAGON
PARAGON
90%
Pursuant to the terms of each of the License Agreements, we are obligated to pay Paragon non-refundable milestone payments of up to $12.0 million under each respective agreement upon the achievement …
Reciprocal relationship from HALO graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from HALO graph: les of five commercial products from the Roche collaboration, two commercial…
WUXI-BIOLOGICS-IRELAND-LIMITED
WUXI-BIOLOGICS-IRELAND-LIMITED
80%
In consideration for the license, we agreed to pay WuXi Biologics a non-refundable milestone payment of up to $1.5 million upon the achievement of certain development milestones.
Reciprocal relationship from JBIO graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from JBIO g…
ant to license agreements with Paragon. If the patent applications mature into one or more issued patents covering ORKA-001 or ORKA-002, we would expect those patents to expire in 2045, absent any ap…
Reciprocal relationship from MLTX graph: LK through Phase 3 development and regulatory approval will require us to expand commercialization preparation activities and incur related expenses before we…
ant to license agreements with Paragon. If the patent applications mature into one or more issued patents covering ORKA-001 or ORKA-002, we would expect those patents to expire in 2045, absent any ap…
Reciprocal relationship from MLTX graph: Reciprocal relationship from ORKA graph: ant to license agreements with Paragon. If the patent applications mature into one or more issued patents covering OR…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ORKA graph: proval, the period of time during which we could market our product candidates under patent protection would be redu…
SNYNF
Sanofi
72%
proval, the period of time during which we could market our product candidates under patent protection would be reduced. Thus, the patents that we may own and license may not afford us any meaningful…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
he forecasted growth, our business may not grow at similar rates, or at all. Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions …
HONG-KONG-LIMITED
HONG-KONG-LIMITED
62%
r terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. 53 We rely on the use of manufacturing suites in th…
PARAGON-THERAPEUTICS-INC
PARAGON-THERAPEUTICS-INC
62%
ses: (a) the Merger was treated as the equivalent of Pre-Merger Oruka issuing stock to acquire the net assets of ARCA, and (b) the reported historical operating results of the combined company prior …
PARUKA-HOLDING-LLC
PARUKA-HOLDING-LLC
62%
Certain patent rights covering ORKA-001 are expected to expire in 2045, absent any applicable patent term adjustments or extensions. Patent rights relating to ORKA-002, if issued, are also expected t…
USA-LLC
USA-LLC
62%
rkets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all. ● Our business is dependent on key personnel, and we may be harmed if we cannot recruit…
WUXI-BIOLOGICS-IRELAND-LIMITED
WUXI-BIOLOGICS-IRELAND-LIMITED
62%
Certain patent rights covering ORKA-001 are expected to expire in 2045, absent any applicable patent term adjustments or extensions. Patent rights relating to ORKA-002, if issued, are also expected t…
Oruka Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ORKA-DEBT-11591
Warrants outstanding: 315356
90%
xbrl warrant detail from xbrl 2025-12-31.
ORKA-DEBT
Debt stack $1.8M
90%
Market cache reports total debt of $1.8M.
ORKA-DEBT-11592
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
Oruka Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Oruka Therapeutics, Inc..
Oruka Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
ORKA-OWNER-FMR-LLC
FMR LLC
90%
13F overlay lists FMR LLC as top holder; 188 tracked holders.
Oruka Therapeutics, Inc. Extended Supply Chain Network
